Biosimilars vs. Interchangeable Biological Products: FDA Fact Check
XTalks
FEBRUARY 8, 2021
Like generic forms of synthetic pharmaceuticals, biosimilars have the advantage of being less costly compared to their branded counterparts. To date, the FDA has approved 29 biosimilars, 19 of which are currently being marketed. MYTH: Clinical pharmacology studies of biosimilars aim to establish safety and effectiveness.
78 
Let's personalize your content